Skip to main content

Table 1

From: Incidence of infections in treatment-experienced (TE) patients in the MOTIVATE studies of maraviroc (MVC) plus optimized background therapy (OBT)

 

MVC (QD+BID) [N = 840]: exposure adjusted incidence*, unadjusted incidence (%)

Placebo [N = 209]: exposure adjusted incidence*, unadjusted incidence (%)

Risk Ratio (exposure adjusted): MVC/PBO (95% CI)

Infections and infestations among sentinel infections/Category C illnesses

27.04, 159 (18.93)

31.37, 33 (15.79)

0.86 (0.59, 1.25)

Selected Category C infections

   

Herpes simplex

4, 24 (2.86)

1.8, 2 (0.96)

2.22 (0.53, 9.40)

Oesophageal Candidiasis

2.5, 15 (1.79)

1.8, 2 (0.96)

1.39 (0.32, 6.07)

Oral Candidiasis

4.7, 28 (3.33)

7.4, 8 (3.83)

0.64 (0.29, 1.39)

Infections and infestations among adverse events

92.80, 447 (53.21)

132.90, 84 (40.19)

0.70 (0.55, 0.88)

Infections AEs of interest

   

Nasopharyngitis

11.3, 67 (7.98)

10.4, 11 (5.26)

1.09 (0.57, 2.06)

Pneumonia

3.1, 19 (2.26)

7.4, 8 (3.83)

0.42 (0.18, 0.96)

Upper RTI

16.1, 94 (11.2)

11.6, 12 (5.74)

1.39 (0.76, 2.53)

Meningitis viral

0.4, 2 (0.2)

0, 0 (0)

ND**

  1. *Adjusted to 100 years of subject exposure;** ND = not defined.